A Phase 3 interventional study of Ibuprofen 600 mg Extended-Release Tablets and Placebo in Pain, Post-Operative Pain and Third Molar Extraction, sponsored by SCOLR Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 16 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-24.
Sponsored by SCOLR Pharma, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies testing ibuprofen in Pain, Postoperative — 7 open to participants now, 8 under way, none of them phase 3. Ibuprofen · Pain, Postoperative.
Among the 56 studies testing ibuprofen in Pain, Postoperative, this one is the 8th largest by enrollment, is the only one that started in 2008, is one of 7 in phase 3, and was the 2nd registered.
5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.
Browse Pain, Postoperative studies →7 of the 56 studies testing ibuprofen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:
University of Puerto Rico · Sites in Puerto Rico
Ages 21–65
University of Michigan · Sites in United States
Ages 12–20
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+ · Women only · Healthy volunteers
Ataturk University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Marquette University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 16 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 8 · Phase 4 24
First in 2004; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.
Median enrollment 100 across the 56 interventional studies. Of the 39 that completed or were terminated, 9 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 56 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with SCOLR Pharma, Inc. as lead sponsor.
SCOLR Pharma, Inc. has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
3 of the studies testing ibuprofen in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07571252University of Puerto RicoImpact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery | 2026-12 |
| NCT05919745Marquette UniversityPreemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft | 2026-12 |
| NCT06495632Cape Fear Valley Health SystemScheduled or as Needed Pain Regimen? | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies testing ibuprofen in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of multiple doses of Ibuprofen 600 mg Extended-Release Tablets in a study of dental pain following extraction of third molar teeth.
This is a single-center, multiple-dose, randomized, placebo-controlled, double-blinded, parallel group trial to evaluate the efficacy and safety of multiple doses of Ibuprofen 600 mg Extended-Release Tablets in a study of dental pain following extraction of third molar teeth. The surgery will consist of surgical extraction of 1-2 impacted third molars, of which one must be a mandibular impaction that is partially impacted in either tissue or bone. Subjects will be stratified according to baseline pain intensity, as rated on an 11-point pain intensity numerical rating scale (PI-NRS)and gender.
5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.
This study's enrollment of 256 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →This is the only study on the registry with SCOLR Pharma, Inc. as lead sponsor.
Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One-hundred and sixty subjects will be randomly assigned to the Ibuprofen 600 mg ER treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
Drug: Ibuprofen 600 mg Extended-Release Tablets
Eighty subjects will be randomly assigned to the Placebo treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
Drug: Placebo
Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
Also known as: Ibuprofen 600 mg ER
Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
Analgesic Efficacy, as Measured by the Sum of Pain Intensity Differences (SPID) Scale
Analgesic efficacy for the 8-12 hour measurement interval after dose 1 using Sum of Pain Intensity Differences (SPID). An 11-point Pain Intensity Numerical Rating Scale (PI-NRS) was used to record pain intensity at baseline and 8, 9, 10, 11, 12 hours after dose 1. The scale went from 0 (no pain) to 10 (Worst possible pain). The outcome measure is based a mean of the sum of each of the five time points evaluated. The total time scale ranges from 0 to 50. Subjects were asked to select the number that best describes how much pain they had at the time of observation.
Time frame: from baseline to 12 hours after dose 1
Durability of Effect as Measured by the Number of Subjects Achieving Meaningful Improvement in Pain Intensity Difference (PID) From Baseline at All Three Assessment Periods of 24, 36, and 48 Hours
Response rate measured the durability of effect and was measured by the number of subjects achieving a reduction of at least 2 points (greater than or equal to 20%) from baseline on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at all 3 assessment periods of 24, 36 and 48 hours. The scale went from 0 (no pain) to 10 (Worst possible pain). Subjects were asked to select the number that best describes how much pain they had at the time of observation.
Time frame: 24, 36, and 48 hours
Time to Confirmed "First Perceptible" Relief
When the subject was administered study medication at Time 0, the Study Coordinator started 2 stopwatches. In an effort to determine the exact moment that the subject began to obtain noticeable pain relief, the subject was instructed to stop the stopwatch when "initial" relief was observed and again when "meaningful" relief was achieved. Time to confirmed first perceptible relief was defined as the time to first perceptible relief, provided that the subject also later stopped the second stopwatch indicating meaningful relief. The assigned censored time for "No Pain Relief" is 240 minutes.
Time frame: Within 4 hours post Dose 1
Time to Confirmed "Meaningful" Relief
When the subject was administered study medication at Time 0, the Study Coordinator started 2 stopwatches. To determine the exact moment that the subject began to notice pain relief, the subject was instructed to stop the stopwatch when "initial" relief was observed and again when "meaningful" relief was achieved. Time to confirmed "meaningful" relief was achieved if both stopwatches were stopped within the 4 hour observation period, when both "initial" and "meaningful" relief were observed. Meaningful relief is a subjective definition, based on each subjects determination of pain.
Time frame: Within 4 hours post Dose 1
Percentage (%) of Subjects With Confirmed First Perceptible Relief Within 1 Hour of Dose 1
Percentage (percentage of total) of subjects with "first perceptible" relief within 1 hour of Dose 1. The assigned censored time for "No Pain Relief" was 240 minutes.
Time frame: Within 1 hour of Dose 1
Percentage of Subjects Achieving "Meaningful" Relief as Indicated by the Time Recorded on the Second Stopwatch Following "First Perceptible" Relief
Percentage(%) of subjects with confirmed first perceptible relief and meaningful relief after dose 1. Subjects that achieved both "first perceptible" relief and "meaningful" relief within the time allotted. The assigned censored time for "No Pain Relief" is 240 minutes. Meaningful relief is a subjective definition, based on each subject's determination of pain
Time frame: Within 4 hours post Dose 1
Analgesic Efficacy for the 0-12, 0-4, 4-8, and 4-12 Hour Dosing Intervals After Dose 1 Using Total Pain Relief (TOTPAR) and Sum of Pain Intensity Difference(SPID)
The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity from baseline pain intensity, so that a higher value was indicative of a greater improvement. Time weighted SPID for each specified interval (scale ranges from 0 to 10; 0=no pain relief and 10= complete pain relief) was derived by first multiplying each PID score by the time from the previous time point, and adding them together for each scheduled time point within the time interval (e.g., 4-12 hours in case of SPID 4-12). Time weighted TOTPAR for each specified interval was similarly derived.
Time frame: 0-12 hours after Dose 1
Duration of Relief After Dose 1
Duration of relief was defined as the time to treatment failure (i.e.,taking rescue medication, or withdrawing due to lack of efficacy) up to the 12-hour time point. For those withdrawing from the study due to lack of efficacy prior to taking dose 2 or rescue medication, time to treatment failure was the time from dose 1 to the last assesment time. For those discontinuing from the study for any other reason, the time to treatment failure was censored at the last assessment time.
Time frame: Time to rescue or time of Dose 2 (up to 12 hours following dose 1)
Percentage of Participants Who Require Rescue Medication at or Prior to Hour 8, Hour 10, and Hour 12 After Taking Dose 1
Percentage of participants who require rescue medication (Lortab) at or prior to hour 8, hour 10 and hour 12 were reported and 95% confidence intervals for the corresponding parameters were calculated.
Time frame: 0-12 hours after taking Dose 1
Pain Relief and PID Scores at Individual Time Points for Dose 1
Pain relief and pain intensity difference (PID) scores at individual time points were summarized by descriptive statistics. The PID at each time point prior to dose 2 was derived by subtracting the pain intensity from the baseline pain intensity, so that a higher value was indicative of a greater improvement. Range of possible scores could be from 0 (no improvement) to 5 (greatest possible improvement)
Time frame: 24, 36, 48 hours after taking Dose 1
Global Evaluation for Dose 1
Global evaluation for dose 1, either at the time of rescue or at dose 2 (hour 12), whichever came first were summarized. At the 12-hour time point but before Dose 2, or within 1 minute of rescue medication use (if it occurred before hour 12), the subject was to provide a Global Evaluation of Dose 1 of study medication on an 11 point PI-NRS in response to the following command: "Select the number that best describes how you would rate this medication as a pain-reliever (select one number only)." The range went from 0 (Very poor) to 10 (Excellent).
Time frame: At 12 hours after Dose 1 or at time of rescue
Global Evaluation, Maximum Relief, and Overall Relief for Dose 2
Global evaluation, maximum relief, and overall relief scores for dose 2 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 2 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).
Time frame: At 24 hours or at time of rescue between 12 and 24 hours
Global Evaluation, Maximum Relief, and Overall Relief for Dose 3
Global evaluation, maximum relief, and overall relief scores for dose 3 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 3 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).
Time frame: At 36 hours or at time rescue between 24 and 36 hours
Global Evaluation, Maximum Relief, and Overall Relief for Dose 4
Global evaluation, maximum relief, and overall relief scores for dose 4 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 4 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).
Time frame: At 48 hours or at time of rescue between 36 and 48 hours.
Date First Subject Enrolled: 24 June 2008 Date Last Subject Enrolled: 11 October 2008 All subjects were to receive 4 doses of study drug or placebo at 12-hour intervals. Of the 12 subjects who prematurely discontinued study drug, 6 subjects received 1 dose of study drug, 2 subjects received 2 doses, and 4 subjects received 3 doses.
| Milestone | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Started | 169 | 87 |
| Completed | 161 | 83 |
| Not completed | 8 | 4 |
| Withdrew: Withdrawal by subject | 8 | 3 |
| Withdrew: Dosed incorrectly | 0 | 1 |
Analgesic efficacy for the 8-12 hour measurement interval after dose 1 using Sum of Pain Intensity Differences (SPID). An 11-point Pain Intensity Numerical Rating Scale (PI-NRS) was used to record pain intensity at baseline and 8, 9, 10, 11, 12 hours after dose 1. The scale went from 0 (no pain) to 10 (Worst possible pain). The outcome measure is based a mean of the sum of each of the five time points evaluated. The total time scale ranges from 0 to 50. Subjects were asked to select the number that best describes how much pain they had at the time of observation.
| Units on a scale | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Analgesic Efficacy, as Measured by the Sum of Pain Intensity Differences (SPID) Scale | 14.80 ± 16.331 | 0.40 ± 11.933 |
Response rate measured the durability of effect and was measured by the number of subjects achieving a reduction of at least 2 points (greater than or equal to 20%) from baseline on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at all 3 assessment periods of 24, 36 and 48 hours. The scale went from 0 (no pain) to 10 (Worst possible pain). Subjects were asked to select the number that best describes how much pain they had at the time of observation.
| participants | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Durability of Effect as Measured by the Number of Subjects Achieving Meaningful Improvement in Pain Intensity Difference (PID) From Baseline at All Three Assessment Periods of 24, 36, and 48 Hours | 123 | 47 |
When the subject was administered study medication at Time 0, the Study Coordinator started 2 stopwatches. In an effort to determine the exact moment that the subject began to obtain noticeable pain relief, the subject was instructed to stop the stopwatch when "initial" relief was observed and again when "meaningful" relief was achieved. Time to confirmed first perceptible relief was defined as the time to first perceptible relief, provided that the subject also later stopped the second stopwatch indicating meaningful relief. The assigned censored time for "No Pain Relief" is 240 minutes.
| Minutes | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Time to Confirmed "First Perceptible" Relief | 42.00 (4 to 81) | 240 (240 to 240) |
When the subject was administered study medication at Time 0, the Study Coordinator started 2 stopwatches. To determine the exact moment that the subject began to notice pain relief, the subject was instructed to stop the stopwatch when "initial" relief was observed and again when "meaningful" relief was achieved. Time to confirmed "meaningful" relief was achieved if both stopwatches were stopped within the 4 hour observation period, when both "initial" and "meaningful" relief were observed. Meaningful relief is a subjective definition, based on each subjects determination of pain.
| Minutes | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Time to Confirmed "Meaningful" Relief | 108 (18 to 240) | 240 (240 to 240) |
Percentage (percentage of total) of subjects with "first perceptible" relief within 1 hour of Dose 1. The assigned censored time for "No Pain Relief" was 240 minutes.
| Percent of participants | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Percentage (%) of Subjects With Confirmed First Perceptible Relief Within 1 Hour of Dose 1 | 62 (54 to 69) | 12 (5 to 18) |
Percentage(%) of subjects with confirmed first perceptible relief and meaningful relief after dose 1. Subjects that achieved both "first perceptible" relief and "meaningful" relief within the time allotted. The assigned censored time for "No Pain Relief" is 240 minutes. Meaningful relief is a subjective definition, based on each subject's determination of pain
| Percent of participants | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Percentage of Subjects Achieving "Meaningful" Relief as Indicated by the Time Recorded on the Second Stopwatch Following "First Perceptible" Relief | 69 (62 to 76) | 17 (9 to 25) |
The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity from baseline pain intensity, so that a higher value was indicative of a greater improvement. Time weighted SPID for each specified interval (scale ranges from 0 to 10; 0=no pain relief and 10= complete pain relief) was derived by first multiplying each PID score by the time from the previous time point, and adding them together for each scheduled time point within the time interval (e.g., 4-12 hours in case of SPID 4-12). Time weighted TOTPAR for each specified interval was similarly derived.
| Time weighted units on a scale | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| TOTPAR 0-12 hours | 54.59 ± 40.830 | 12.05 ± 27.114 |
| TOTPAR 0-4 hours | 16.84 ± 11.854 | 3.18 ± 6.749 |
| TOTPAR 4-8 hours | 25.94 ± 19.013 | 5.34 ± 12.393 |
| TOTPAR 4-12 hours | 43.38 ± 33.851 | 9.92 ± 23.411 |
| SPID 0-12 hours | 37.20 ± 34.791 | 0.45 ± 24.378 |
| SPID 0-4 hours | 11.64 ± 10.222 | -0.18 ± 6.591 |
| SPID 4-8 hours | 17.88 ± 16.158 | 0.24 ± 11.034 |
| SPID 4-12 hours | 29.49 ± 28.654 | 0.67 ± 20.617 |
Duration of relief was defined as the time to treatment failure (i.e.,taking rescue medication, or withdrawing due to lack of efficacy) up to the 12-hour time point. For those withdrawing from the study due to lack of efficacy prior to taking dose 2 or rescue medication, time to treatment failure was the time from dose 1 to the last assesment time. For those discontinuing from the study for any other reason, the time to treatment failure was censored at the last assessment time.
| Minutes | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Duration of Relief After Dose 1 | 720 (1 to 720) | 101 (1 to 720) |
Percentage of participants who require rescue medication (Lortab) at or prior to hour 8, hour 10 and hour 12 were reported and 95% confidence intervals for the corresponding parameters were calculated.
| Percentage of participants | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Rescue at or prior to 8 hours after dose 1 | 31.4 (24 to 38) | 82.8 (75 to 91) |
| Rescue at or prior to 10 hours after dose 1 | 34.9 (28 to 42) | 85.1 (78 to 93) |
| Rescue at or prior to 12 hours after dose 1 | 36.1 (29 to 43) | 85.1 (78 to 93) |
Pain relief and pain intensity difference (PID) scores at individual time points were summarized by descriptive statistics. The PID at each time point prior to dose 2 was derived by subtracting the pain intensity from the baseline pain intensity, so that a higher value was indicative of a greater improvement. Range of possible scores could be from 0 (no improvement) to 5 (greatest possible improvement)
| Units on a scale | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| 24 hours after dose 1. | 3.11 ± 3.466 | 0.18 ± 2.599 |
| 36 hours after dose 1. | 3.10 ± 3.460 | 0.22 ± 2.704 |
| 48 hours after dose 1. | 3.44 ± 3.756 | 0.22 ± 2.721 |
Global evaluation for dose 1, either at the time of rescue or at dose 2 (hour 12), whichever came first were summarized. At the 12-hour time point but before Dose 2, or within 1 minute of rescue medication use (if it occurred before hour 12), the subject was to provide a Global Evaluation of Dose 1 of study medication on an 11 point PI-NRS in response to the following command: "Select the number that best describes how you would rate this medication as a pain-reliever (select one number only)." The range went from 0 (Very poor) to 10 (Excellent).
| Units on a scale | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Global Evaluation for Dose 1 | 6.05 ± 3.536 | 1.79 ± 2.898 |
Global evaluation, maximum relief, and overall relief scores for dose 2 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 2 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).
| Units on a scale | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Global Evalution for Dose 2 | 6.82 ± 2.914 | 4.24 ± 3.673 |
| Maximum Relief for Dose 2 | 7.27 ± 2.997 | 5.02 ± 3.864 |
| Overall Relief for Dose 2 | 6.62 ± 3.005 | 4.46 ± 3.588 |
Global evaluation, maximum relief, and overall relief scores for dose 3 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 3 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).
| Units on a scale | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Global Evaluation for Dose 3 | 7.14 ± 2.839 | 4.98 ± 3.549 |
| Maximum Relief for Dose 3 | 7.61 ± 2.922 | 5.63 ± 3.805 |
| Overall Relief for Dose 3 | 6.76 ± 2.942 | 5.02 ± 3.634 |
Global evaluation, maximum relief, and overall relief scores for dose 4 were summarized with descriptive statistics. The subject was to provide a description for the Global Evaluation, maximum relief and overall relief of Dose 4 of study medication on an 11 point PI-NRS: Global Evaluation: "rate the study medication as a pain-reliever"; Maximum Pain Relief: "maximum pain relief received from the last dose"; Overall Pain Relief: "overall quantity of pain relief received from the last dose". The range went from 0 (Very poor or No relief) to 10 (Excellent or Complete relief).
| Units on a scale | Ibuprofen 600mg ER | Placebo |
|---|---|---|
| Global Evalution for Dose 4 | 7.26 ± 2.953 | 4.70 ± 3.715 |
| Maximum Relief for Dose 4 | 7.66 ± 2.970 | 5.34 ± 3.970 |
| Overall Relief for Dose 4 | 7.06 ± 3.045 | 4.89 ± 3.803 |
Non-serious events are listed at a 0.35% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibuprofen 600mg ER | — | 0/169 (0%) | 0/169 (0%) |
| Placebo | — | 0/87 (0%) | 0/87 (0%) |
| Age, Categorical(Participants) | Ibuprofen 600mg ER | Placebo | Total |
|---|---|---|---|
| <=18 years | 64 | 35 | 99 |
| Between 18 and 65 years | 105 | 52 | 157 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Ibuprofen 600mg ER | Placebo | Total |
|---|---|---|---|
| Mean | 18.9 ± 3.22 | 18.8 ± 3.25 | 18.9 ± 3.22 |
| Sex: Female, Male(Participants) | Ibuprofen 600mg ER | Placebo | Total |
|---|---|---|---|
| Female | 95 | 47 | 142 |
| Male | 74 | 40 | 114 |
| Region of Enrollment(participants) | Ibuprofen 600mg ER | Placebo | Total |
|---|---|---|---|
| United States | 169 | 87 | 256 |
The record gives a start of Jun 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen